GCG and Insulin resistance: More precisely, in a (DIO) mouse model, treatment with dual GLP-1/GIP RAs led to decreased fasting glucose and insulin and improved Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) levels, as well as lower cholesterol, LDL, and apolipoprotein levels [74], in both male and female DIO mice compared with GLP-1 or GIP mono-agonist-treated mice [74,75].